{"id":39270,"date":"2026-01-21T10:02:08","date_gmt":"2026-01-21T09:02:08","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=39270"},"modified":"2026-01-16T14:05:25","modified_gmt":"2026-01-16T13:05:25","slug":"doak-antidot-wegen-fehlender-einigung-mit-zulassungsbehoerden-in-den-usa-vom-markt-genommen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2026\/doak-antidot-wegen-fehlender-einigung-mit-zulassungsbehoerden-in-den-usa-vom-markt-genommen","title":{"rendered":"DOAK-Antidot wegen fehlender Einigung mit Zulassungsbeh\u00f6rden in den USA vom Markt genommen [CME]"},"content":{"rendered":"<p>Der zur Antagonisierung der Direkten Oralen Antikoagulanzien (DOAK) Apixaban (Eliquis\u00ae) und Rivaroxaban (Xarelto\u00ae) zugelassene Arzneistoff Andexanet alfa (EU: Ondexxya\u00ae; USA: Andexxa\u00ae; Hersteller AstraZeneca) ist in den USA seit 22. Dezember 2025 nicht mehr kommerziell verf\u00fcgbar. Der Hersteller hat das Pr\u00e4parat \u201efreiwillig\u201c vom Markt genommen, nachdem die US-amerikanische Zulassungsbeh\u00f6rde FDA \u201edas Risiko h\u00f6her als den Nutzen\u201c [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Der zur Antagonisierung der Direkten Oralen Antikoagulanzien (DOAK) Apixaban (Eliquis\u00ae) und Rivaroxaban (Xarelto\u00ae) zugelassene Arzneistoff Andexanet alfa (EU: Ondexxya\u00ae; USA: Andexxa\u00ae; Hersteller AstraZeneca) ist in den USA seit 22. Dezember 2025 nicht mehr kommerziell verf\u00fcgbar. Der Hersteller hat das Pr\u00e4parat \u201efreiwillig\u201c vom Markt genommen, nachdem die US-amerikanische Zulassungsbeh\u00f6rde FDA \u201edas Risiko h\u00f6her als den Nutzen\u201c [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5190,5197,6309,137,1322,2305,1314,1312,6310,1327,2304],"class_list":["post-39270","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-andexanet-alfa","tag-annexa-4-studie","tag-annexa-i-studie","tag-antikoagulanzien","tag-apixaban","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edixaban","tag-noak","tag-rivaroxaban"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/39270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=39270"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/39270\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=39270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=39270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=39270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}